SEC 13F Intelligence

Managers / Q2 2023 · view latest →

Lion Point Capital, LP

CIK 0001643354 · 375 PARK AVE, SUITE 2609, NEW YORK, NY, 10152 · 212-356-6200

Reported Value
$221M
Q2 2023
Positions
30
Filings on Record
31
2019–present window
Filed
Aug 14, 2023
original filing

Summary

Lion Point Capital, LP reported $221M in U.S.-listed holdings across 30 positions for Q2 2023.

The portfolio is heavily concentrated: SMTC alone accounts for 28.2% of reported value.

Compared with Q1 2023, the fund opened 5 new positions and exited 7.

Portfolio Metrics

Turnover
+34.9%
vs prior filed quarter
Top-10 Concentration
+56.1%
share of reported value
Largest Position
+28.2%
Semtech
New / Exited
5 / 7
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $636MQ4 ’18Q1 ’19: $1.1BQ2 ’19: $1.0BQ3 ’19: $897MQ4 ’19: $1.1BQ4 ’19Q1 ’20: $379MQ2 ’20: $412MQ3 ’20: $456MQ4 ’20: $519MQ4 ’20Q1 ’21: $550MQ2 ’21: $579MQ3 ’21: $533MQ4 ’21: $373MQ4 ’21Q1 ’22: $431MQ2 ’22: $878MQ3 ’22: $454MQ4 ’22: $703MQ4 ’22Q1 ’23: $243MQ2 ’23: $221MQ3 ’23: $224MQ4 ’23: $200MQ4 ’23Q1 ’24: $179MQ2 ’24: $55MQ3 ’24: $45MQ4 ’24: $19MQ4 ’24Q1 ’25: $16MQ2 ’25: $15MQ3 ’25: $18MQ4 ’25: $19MQ4 ’25Q1 ’26: $17Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 87.3%ETP: 10.0%Other: 2.6%
  • Common Stock · 87.3% · $193M
  • ETP · 10.0% · $22M
  • Other · 2.6% · $6M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
BLUEBIRD BIO INCNEW+531.3K531.3K+$2M$2M
FRXFENNEC PHARMACEUTICALS INCNEW+110.0K110.0K+$971,300$971,300
HORIZON THERAPEUTICS PUB LNEW+7.4K7.4K+$761,090$761,090
SNDXSYNDAX PHARMACEUTICALS INCNEW+34.5K34.5K+$722,085$722,085
WHWKAADI BIOSCIENCE INCNEW+82.4K82.4K+$563,773$563,773
HARPOON THERAPEUTICS INCADDED+287.2K456.5K+$198,145$324,125
SMTCSEMTECH CORPADDED+2.50M4.95M+$67M$126M
ARCONIC CORPORATIONSOLD OUT−712.4K0−$19M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2023

26 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SMTCSEMTECH CORPhistory →COM28.22%$62M2.45M
2MARINUS PHARMACEUTICALS INCCOM NEW11.08%$25M2.26M
3CHRDCHORD ENERGY CORPORATIONhistory →COM NEW7.12%$16M102.4K
4ARDXARDELYX INChistory →COM2.34%$5M1.53M
50LSBURGERFI INTERNATIONAL INChistory →COM1.95%$4M2.75M
6MCRB1EURSERES THERAPEUTICS INChistory →COM1.50%$3M691.8K
7DC8ADURECT CORPhistory →COM NEW1.35%$3M601.7K
8BATLBATTALION OIL CORPCOM0.98%$2M380.9K
9KINIKSA PHARMACEUTICALS LTDCOM CL A0.83%$2M130.7K
10BLUEBIRD BIO INCCOM0.79%$2M531.3K
11MISTMILESTONE PHARMACEUTICALS INCOM0.58%$1M450.2K
12ACRSACLARIS THERAPEUTICS INCCOM0.51%$1M109.9K
13TSVT*2SEVENTY BIO INCCOMMON STOCK0.51%$1M111.7K
14CYMABAY THERAPEUTICS INCCOM0.49%$1M99.4K
15IM8NINSMED INCCOM PAR $.010.48%$1M50.3K
16FRXFENNEC PHARMACEUTICALS INCCOM0.44%$971,300110.0K
17HORIZON THERAPEUTICS PUB LSHS0.34%$761,0907.4K
18SNDXSYNDAX PHARMACEUTICALS INCCOM0.33%$722,08534.5K
19MIRMMIRUM PHARMACEUTICALS INCCOM0.32%$698,49027.0K
20WHWKAADI BIOSCIENCE INCCOM0.25%$563,77382.4K
21ORIGIN MATERIALS INCCOM0.19%$426,000100.0K
22HARPOON THERAPEUTICS INCCOM0.15%$324,125456.5K
23LUMOS PHARMA INCCOM0.12%$258,55878.4K
24MSFTMICROSOFT CORPCOM0.02%$34,054100
25GOOGALPHABET INCCAP STK CL C0.01%$12,097100
26PDCEUSDPDC ENERGY INCCOM0.00%$7,114100

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$17M35May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$19M39Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$18M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$15M19Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$16M21May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$19M19Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$45M25Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$55M27Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$179M32May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$200M30Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$224M31Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$221M30Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$243M31May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$703M32Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$454M41Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$878M40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$431M35May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$373M33Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$533M38Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$579M34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$550M30May 19, 2021RESTATEMENTchanges · EDGAR ↗
Q4 2020$519M24Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$456M24Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$412M24Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$379M25May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.1B26Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$897M26Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.0B24Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.1B24May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$636M35Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.